Skip Nav Destination
![]()
You do not currently have access to this content.
Next-Generation TKI Effective against ALK-Positive NSCLC
September 27, 2024
NVL-655, a fourth generation ALK tyrosine kinase inhibitor, was effective and well tolerated in the ALKOVE-1 trial in patients with ALK-positive non–small cell lung cancer that had previously been treated with earlier-generation ALK inhibitors, including lorlatinib.
RSS Feeds